Theranexus
Developing drug combinations that consist of one compound that targets neurons and another that modulates the activity of astrocytes.
Market cap
$8.8m
Enterprise value
$11m
Share price
€1.14 ALTHX.PA
Company register number
791889777
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Early VC | |
| Total Funding | 000k | ||
Auriga Partners(exited)
CEA Investissement(exited)
Rhone-Alpes Creation(exited)
Sofimac Régions(exited)
Wilco(exited)
D Language(exited)
PAR(exited)
Sofimac Innovation(exited)
Phitrust Impact Investors(exited)
Auriga Partners (Paris)(exited)
Supernova Invest(exited)
Sofimac Partners(exited)
CEA(exited)
Incuballiance Paris-Saclay(exited)
CEA-Leti(exited)
Injectpower(exited)
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.